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Smumary The efficacy of radioimmunotherapy of tumours with radiolabelled monoclonal antibodies (MAbs)
depends on the amount of antibody taken up by the tumour and on its intratumoral distribution. In the case
of MAbs directed against intracellular antigens, increasing the permeability of the cytoplasmic membrane may
augment the bioavailability of the antigen for the antibody. This raises the question whether the induction of
tumour necrosis by chemotherapy can enhance the tumour uptake of radiolabelled monoclonal antibodies. In
this work, the effect of doxorubicin on the biodistribution of Po66, an MAb directed against an intracellular
antigen, was studied in nude mice grafted with the human non-small-cell lung carcinoma cell line SK-MES-1.
After injection on day 0 of "WI-labelled Po66, tumour radioactivity increased up to days 3-5, and then
remained unchanged to day 14. The combined administration of 11I-labelled Po66 with 8 mg kg-' dox-
orubicin, in two doses separated by 7 days, doubled the radioactivity retained by the tumour. Histological and
historadiographic analysis showed, however, that the drug induced cellular damage. In the absence of
doxorubicin, the accumulation of Po66 was restricted to some necrotic areas, whereas with doxorubicin the
necrosis was more extensive and the antibody more evenly distnrbuted. These results suggest that
chemotherapy and immunoradiotherapy combined would enhance tumour uptake of radioisotope and pro-
mote more homogenous distribution of the radiolabelled MAb. This would promote eradication of the
remaining drug-resistant cells in tumours.
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Monoclonal antibody-targeted radiotherapy relies on differ-
ential radioisotope uptake in tumour and tissues. This first
requires that the amount of circulating radiolabelled mono-
clonal antibody (MAb) should be as low as possible to
minimise non-specific irradiation of normal tissues. Second,
the tumour uptake of MAb should be as elevated and long-
lasting as possible to deliver sufficient radiation to the
tumour.
Several techniques have been devised to overcome the
non-specific irradiation due to persistence of the radiolabelled
MAb in the circulation. Among these are the use of F(ab')2
fragments, which are cleared rapidly from blood (Buchsbaum
et al., 1990; Sharkey et al., 1990), and the injection of a
second antibody provoking the formation of immune com-
plexes, which are rapidly eliminated from blood (Blumenthal
et al., 1988). Unbound antibody can also be removed from
the circulation by means of immunoadsorption (Lear et al.,
1991). Non-speific irradiation should be minimised by the
use of two-step MAb-targeting techniques, combining first
the administration of bifunctional (Le Doussal et al., 1989;
Bosslet et al., 1991) or pretargeted MAbs (streptavidinylated
or enzyme conjugated) (Kalafonos et al., 1990; Hawkins et
al., 1993), and second the injection of hapten-, biotin- or
substrate-bound radionucides, which are rapidly cleared
from blood.
The amount of MAb taken up by tumours depends on
several biological parameters, such as molecular size, the
specificity and affinity of the MAb, the amount and location
of the anitgen, as well as tumoral size, vasculature and
interstitial pressure (Jain, 1990) and the host response to
foreign immunoglobulin (Reynolds et al., 1989). As a general
rule, the proportion of MAb taken up by the tumour is low
(0.001-0.1% of the injected dose in man), and distribution of
MAbs within the tumours is heterogeneous. Accordingly,
several techniques have been proposed to enhance the
tumour uptake of MAbs. An increase in MAb affinity can
enhance tumour uptake of MAbs (Schlom et al., 1992). The
use of F(ab')2 or Fab fragments improves penetration of
tumours (Endo et al., 1988; Buchsbaum et al., 1990; Sharkey
et al., 1990). The amount of MAb injected can be increased
until antigenic sites are saturated (Goodman et al., 1993).
The use of several MAbs of different specificity, or recognis-
ing different epitopes of the same tumour-associated antigen
(Buchegger et al., 1989), increases antibody uptake. It has
also been proposed to increase tumour antigen expression
with interferon (Rosenblum et al., 1988), or to modify
tumoral vasculature with interleukin 2 (Nakamura et al.,
1994) or interleukin 2 immunoconjugate (LeBerthon et al.,
1991) in order to improve the accessibility to tumour
antigens.
With MAbs directed against intracellular antigens, the
ability of the antibody to reach its target depends on tumour
cell membrane permeability. The latter is increased at various
stages of the cell degeneration process which occurs spon-
taneously in tumours, even at an early stage of their growth
(Cooper et al., 1975). Tumour necrosis may be increased by
chemotherapy. This results in enhanced accessibility of intra-
cytoplasmic tumour antigens to MAbs. In this study, we used
a tumour-bearing mouse model, to described the biodistribu-
tion of Po66, an MAb directed against a still unknown
cytoplasmic antigen present in non-small-cell lung carcinoma.
We show that administration of doxorubicin enhances the
uptake of '"-I-radiolabelled Po66 by tumours and improves
the homogeneity of the distribution of the MAb throughout
the tumours.
Materials and methods
Production and radioiodination ofmonoclonal antibodies
MAb Po66, a mouse IgGI, was obtained as described
previously (Dazord et al., 1987). Briefly, Balb/c were
immunised with enzymatically dissociated cells from a
patient's lung squamous cell carcinoma. Mouse immune cells
were fused with SP2/0 plasmocytoma and MAb Po66 was
selected from the hybrids obtained. Po66 consistently reacted
with squamous cell carcinomas and half of the adenocar-
cinomas tested, but not with small-cell lung carcinoma. MAb
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Po66 bound to a 47 kIDa cytoplasmic glycoprotein (Martin et
al., 1989). It did not recognise normal tissues except distal
renal tubules and gastric and bronchial serous glands. The
Po66 batch used in the present work was purified from
ascites obtained from hybridoma i.p. grafted Balb/c mice.
The ascites fluid was precipitated in 40% saturated
ammonium sulphate, dialysed against 10 mM phosphate
buffer, pH 8 and eluted from a DEAE ion-exchange column
with a 10-150mM, pH8 phosphate buffer gradient. A
mouse monoclonal immunoglobulin, Py, without known
specificity, was taken as control and procesed like Po66.
Samples of Po66 and Py were radioiodinated with iodine-
125 by the iodogen method and separated from free iodine
by elution through a Dowex anionic exchange column
equilibrated with phosphate-buffered saline (PBS) contng
0.3% human serum albumin, as described. The protein-
bound radioactive fraction averaged 90%.
solution and washed. The tissues were then counterstained
with haematoxylin-eosin.
Chemotherapy
Doxorubicin (Adriblastin, Farmitalia Carlo Erba, Rueil Mal-
maison, France) was chosen because it is active on growth of
non-small-cell lung carcinoma xenografts (Boven et al.,
1992). Two i.v. injections (8 mg kg-') separated by 7 days
were given. The weight loss of mice was only 7% at this
dosage regimen.
Statistical analysis
Statiscal analysis was performed using Student's unpaired
t-test.
Cell line
SK-MES-1, a human squamous cell carcinoma line (Amer-
ican Type Culture Collection HTB 58, 1990), was grown in
RPMI-1640 medium (AES, Combourg, France) supple-
mented with 10% fetal calf serum (Anval, Betton, France),
2 mM glutamine and 80 mg 1' gentamycin, at 37C in a fully
humidified atmosphere of 95% air:5% carbon dioxide. Cells
at confluence were trypsinised from monolayer cultures,
washed twice in PBS and resuspended in RPMI-1640 before
inoculation into mice.
Tumour model
Female athymic mice (nu/nu) (6-8 weeks old) were obtained
from Janvier (53590 St Berthevin, France). They were
inoculated s.c. (0.1 ml) with 5 x 10' SK-MES- in the right
flank. The tumours reached a 0.6-0.8 cm diameter within 3
weeks after injection. During the experiments, water with
potassium iodide (0.2%) was available ad libitum.
Biodistribution studies
Tumour-bearing mice were given injections of "WI-labelled
antibodies (6 MBq) in the tail vein. The animals were anaes-
thetised at various times after i.v. injection, bled and
sacrificed. Blood, tumours and organs (lung, spleen, liver,
kidney, bone, small boweL stomach, muscle) were removed,
weighed and their radioactivity was counted in a gamma
counter (CG 4000 intertechnique). The labeled antibody dis-
tributions for blood, tumour and organs were expressed as
percentages of the injected dose per gram of tissue
(% ID g-'). In some experiments, the results were expressed
as plg of radiolabelled Po66 per gram of tissue gg'), a
value inferred from % ID g-'. To determin whether blood
radioactivity was related to antibody-radioiodine conjugate
and not to free iodine, serum samples were precipitated with
TCA. About 95% of blood radioactivity was protein bound
at each time point.
Histology
The reactivity of MAb with tumour antigen was demon-
strated by the immunoperoxidase staining procedure des-
cribed by Hsu et al. (1981). Briefly, sections were incubated
for 2 h with MAb Po66 in l0-3 diluted ascites or with
normal mouse serum controls, washed with PBS, incubated
with biotinylated anti-mouse IgG antibody, washed and
exposed to the avidin-biotin-peroxidase complex (vectastai
vector). Peroxidase was stained by the diaminobenzidine
reaction.
For autoradiographic studies, 5 pm tissue sections were
deparaffinised in xylene, dipped in alcohol, rehydrated and
processed as follows. The sections were dried and coated with
radiographic emulsion (Ilford K5). After 14 days' incubation
at 4-C in dehydrated light-tight boxes, the slides were
developed in Kodak L x 24 for 5 min, fixed in Ilford Hypam
Resuts
Organ distribution ofPo66 in the absence ofcombined
doxorubicin treatment
The biodistribution of Po66 was measured in tumour-bearing
mice, from 4h to 14 days after i.v. injection of 50Opg of
'5I-radiolabelled Po66 (['"1]Po66). The results, reported in
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Figure la. show that the peak accumulation occurred
between days 3 and 5. with 6.4 ± 1.3 and 7.1 ± 0.8% ID g-'
of tumour respectively (mean ± s.d.). The radioactivity
uptake remained elevated for at least 14 days (6.1 ± 0.9%
ID g-') in the tumour while decreasing in the blood and
organs (Table I). Figure lb shows that the tumour uptake of
the unrelated '25I-labelled Py MAb was 2-3 times lower than
that of["UI]Po66 after 24 h. while it did not differ in normal
tissues. These results are in agreement with previous reports
using human lung carcinoma xenografts (Desrues et al.,
1989).
Immunoperoxidase staining of tissue sections of SK-MES-
I tumours showed that the antigen recognised by Po66 was
present in almost all tumour cells and that the dye was
distributed homogeneously throughout the tumour, i.e. in
both apparently viable cells and necrotic cells (figure not
shown). To determine the microscopic location of antibodies
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Fge 2 Autoradiographs of SK-MES- carcinoma excised
from nude mice injected i.v. with ['flMAbs, 5 days before
sampling. (a) At low magnification ( x 5) after Po66 injection,
silver grains are located in a limited area that corresponds to
necrosis. There is no binding to viable cells. (b) At higher
magnification (x 20), in necrotic areas, radiolabelled Po66 binds
to residual ghost cells. (c) After injection of the unrelated '"I-
labelled IgGl, Py, a non-specific distribution of silver grains is
seen.
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in tumour-bearing nude mice, autohistoradiographic studies
were performed on tumours excised 5 days after injection of
['5l]Po66 or ['"I]Py. As shown in Figure 2a, at low
magnifiation, ['lI]Po66 clearly bound to the central necrotic
area of the tumours. At higher magnificton (Figure 2b), the
label was distributed diffusely in the necrotic area asciated
with residual anucleated cells or amorphous zones of debris.
In ["I']Py-injected mice (Figure 2c), there was no specific
area of binding of radioactivity within the tumour. Thus the
autoradiographic investigations showed that ['2I]Po66 pre-
ferentialiy bound to degenerating tumour cells. This was in
agreement with a previous demonstration of the intracyto-
plasmic location of the antigen recognised by Po66 (Martin
et al., 1989) and explained why the antigen could only be
reached by the MAb when the cell membrane was becoming
permeable to macromolecules like immunoglobulins.
As the biodistribution curve of Po66 showed a plateau of
accumulation in the tumour between days 3 and 5 and day
14, the effect of a dose escalation of [1'IJPo66 was measured
on days 5 and 14. Groups ofthree or four mice were injected
i.v. with increasing amounts of ['lI]Po66 (25, 50, 100 and
200pg). As shown in Figure 3, when data were expresed as
pg of Po66 per gram of tissue, a dose-related increase in
blood radioactivity was observed. In contrast, tumour
radioactity uptake reached a plateau beyond 100pg. These
data suggest that above doses of 100pg the accebl antigen
recognised by Po66 was saturated.
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Organ distribution ofPo66 combined with doxorubicin
treatment
As Po66 bound to an intracytoplasmic antigen, we attempted
to improve its accebility by combining antibody injection
with doxorubicin. Po66 was injected on day 0 and two
schedules of administration of doxorubicin were compared.
Doxorubicin (8mgkg-') was injected twice i.v., (I week
interval), either on days -7 and 0 (D - 7/DO), or on days 0
and + 7 (DO/D + 7). Biodistribution was evaluated 3, 5, 9
and 14 days after administration of 50pg of [mI]Po66. As
shown in Figure 4, doxorubicin n twice i.v. (I
week interval) transiently decreased the growth curve of
tumours in the time course of the experiments. This
difference was not statistically siifnt, and 14 days after
the last injection, the slope of the curve of tumour growth in
the doxorubicin-treated group was similar to the slope of the
control tumours. The extent of necrosis was determined his-
tologicaily. In non-treated mice an average of 1-2 areas of
necrosis were present in the central part oftumours (15-30%
of the section area), although in doxorubicin-treated mice
3-4 areas ofmore extended necrosis were observed (40-70%
of the section area). Figures 2a and 5a are representative of
the appearance and the extent of necrosis in control and
doxorubidn-treated mice. In the D - 7/DO schedule, how-
ever, the necrosis was less extensive on day 14 than on day 5.
Figure 6 shows the % IDg-' of tumour in control and
doxorubicin-treated mice. Wben doxorubicin was admin-
istered on day -7 and day 0, a 2-fold increase in ['"IJPo66
uptake (compare controls) was observed in tumours on days
3 and 5 (13.9 ±2 and 13.1 ±1.1%IDgI restively
P<0.05). Tumour uptake was still elvated on day 9, but
did not differ si ntly from the controL and returned to
control vahls on day 14. When doxorubicin was admin-
istered on day 0 and day + 7, a statistically sigict in-
crease in tumour uptake was observed on days 5 and 9. This
uptake remained elevated on day 14 (9.2 ± 0.7% ID g-' vs
6.1 ± 0.9% IDg-' for control; P= 0.05). Doxorubicin did
not interfere with the uptake of Po66 by normal issues
(Table 1). Po66 binding to tumours was dependent on the
dose of doxorubicin injected and no increased radioactivity
binding to tumours was observed with 4mg kg-' dox-
orubidn (6.4 ± 1.4 and 5.8 ± 0.6% ID g-' oftumour on days
5 and 14 respectively, for the DO/D + 7 schedule, n = three
mice).
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Figre 5 Autoradiographs of SK-MES-1 tumours excised from
nude mice injected with 50 Lg of[':I]Po66 and doxorubicin. Po66
was injected on day 0, doxorubicin on days - 7 and 0, and the
tumour was sampled on day 5. (a) At low magnification (x 5),
several large areas of necrosis with bound silver grains. (b) At
higher magnification (x 20), between areas of necrosis, degener-
ative tumour cells covered with silver grains (arrow heads) are
intermixed with presumably viable unlabelled cells.
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Autohistoradiographic analysis was performed on tumours
removed from mice pretreated with doxorubicin (D -7DO)
and sacrificed 5 days after i.v. injection of [`DI]Po66. Figure
5a clearly shows, at low magnification, that in contrast to
controls (Figure 2a), treatment with doxorubicin induced
numerous necrotic areas that bound silver grains. At higher
magnification (Figure 5b), in areas adjacent to necrosis,
many spots of silver grain were observed, and were probably
related to the binding of ['"I]Po66 to degenerating cells.
Necrosis was, therefore. accompanied by a more homo-
geneous distribution of radiolabelled Po66 in tumours.
As reported above (Figure 3), the uptake of radiolabelled
Po66 by the tumour reached a plateau for an injection of
above 100;g MAb per mouse. This plateau was examined in
doxorubicin-treated mice. The administration of doxorubicin
significantly increased the tumour uptake of 200 tg of
['VI]Po66 on day 5, particularly when doxorubicin was
administered before Po66 (D -7DO; Figure 7). On day 14,
according to previous observations, the tumour uptake was
higher when doxorubicin was administered with the DO,
D + 7 schedule. This phenomenon is probably due to the fact
that more antigenic sites were accessible after doxorubicin
treatment.
Po66, like other MAbs directed against intracellular antigens
(Epstein et al., 1988). binds predominantly to necrotic areas
of tumours. This is probably because of the ability of the
MAb to cross damaged cytoplasmic membranes. The most
important problem raised by such antibodies is that they
cannot reach their target in viable cells. Also, the access of
the MAb to the necrotic zones may be difficult, owing to
unfavourable physicochemical conditions in the central parts
of bulky tumours with poor vasculature. and altered pH and
hydrostatic pressure (Jain, 1990). Another limitation for these
MAbs is that the amount of accessible antigen depends on
the degree of necrosis, which is variable and unpredictable.
MAbs directed against internal antigens may have, how-
ever, several advantages. First, the intracytoplasmic localisa-
tion offers a double binding specificity:antigen-antibody
interaction, and access to antigen only in damaged tumour
cells, a specific pattern of tumours, even at an early stage of
development (Cooper et al., 1975). Such MAbs cannot bind
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Figre 6 Radioactivity uptake of ['25I]Po66 by untreated or
doxorubicin-treated tumours. ['"I]Po66 was injected i.v. on day 0
and doxorubicin was administered i.v. either on days - 7 and 0
or on days 0 and + 7. n =five mice for each time point.
*Significant difference for P<0.05. 0, Control; 0, doxorubicin
(D - 7/DO); U, doxorubicin (DO,D + 7).
Fire 7 Tumour radioactivity uptake 5 and 14 days after injec-
tion of 200iLg of ["UIJPo66 on day 0, in tumour-bearing mice
treated with doxorubicin on days - 7 and 0, or 0 and + 7.
*Significant difference for P<0.05. [, Control; _, dox-
orubicin (D - 7 DO); _, doxorubicin (DO/ID + 7).
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to normal tssues even if these tissues express the antigen.
Second, the 'binding site barrier' effect described by Wein-
stein et al. (1992) does not seem to apply to intracellular
antigens. This effect consists of a limitation of antibody
penetration in tumours due to a preferential uptake by easily
accessible antigen sites of tumour nodules. We demonstrated
here with Po666 that the MAb penetrated the central nec-
rotic cores of the tumours. This was to be expected from in
vitro models which showed good diffusion of MAbs through-
out thee-dimensional culture systems (Carisson et al., 1989;
Dazord et al., 1993). Third, another important advantage of
anti-internal antigen antibodies is their prolonged retention
time in the tumours (Welt et al., 1987). Po66 was still
detected at high levels in the tumour up to 14 days post
injection. In man, Po66 was also found to persist for a long
time (Bourguet et al., 1990). This situation is very favourable
for the two-step therapies described in the introduction.
Fourth, as shown here with Po66, it was possible to enhance
tumour uptake of the MAb by means of chemotherapy. This
correlated with the induction of necrosis as observed his-
tologically. However, it remains possible that doxorubicin
treatment increases tumour blood flow by dilating vessels
near the necrotic areas, thus leading to increased antibody
delivery, as has been shown with radiation and hyperthermia
(Stickney et al., 1987). In the D - 7/DO protocol, the uptake
of Po66 was more elevated than in controls on days 3 and 5,
but identical on day 14. This is probably due to a repopula-
tion of the tumour by new dividing cells, 2 and 3 weeks after
treatment with doxorubicin, as would be expected from the
growth curve. When doxorubicin was on days 0
and 7, high uptake on days 9 and 14 was observed, suggest-
ing that this protocol of doxorubicin administration main-
tained necrosis within tumours and probably allowed more
persistent access to the antigen by Po666 rather than
doxorubicin-induced trapping of the MAb in new necrotic
areas. This suggests that for an optimal effect, chemotherapy
and radiolabelled MAb should be separated by a relatively
short interval.
In terms ofradiolabeled MAbs as potential tools in cancer
treatment, the present investigation in a mouse model leads
to some speculations. As shown in Figure 2a, it is possible
that a medium-range radioisotope like iodine-131 would not
reach and destroy distant viable cells at the edge of the
tumour. However, sequential injection of radiolabelled
antibody could produce an ever expanding population ofnew
target cells in the tumour as a result of the centrifual lling
ofadjacent viable tumour cells, as has been shown previously
with an antibody directed against an intracellular antigen
(Chen et al., 1989). However, the combination of chemo-
therapy with radiolabelled MAbs directed against a cytoplas-
mic antigen might produce a synergistic effect. Improved
diffusion of the MAb throughout the tumour may result in
the irradiation of the last drug-resistant cells, by a cross-fire
effect from all necrotic areas induced by chemotherapy. The
treatment would be particularly beneficial for small scattered
metastases. The question arises whether the combination of
both drugs would also enhance bone marrow toxicity. It is
important to note that the antigen recognised by Po66 is not
present in haematopoietic cells (Dazord et al., 1987), and that
the lysis ofthese cells by the associated chemothereapy would
not sensitise them to irradiation as intensely as tumour cells.
In contrast, MAbs directed against ubiquitous intracellular
antigens like histones (Epstein et al., 1988) could have such
an effect.
On the other hand, it is likely that the non-specific irradia-
tion due to cirulating radiolabelled MAb, combined with
chemotherapy, would prove toxic for haematopoietic bone
stem cells. Although bone marrow support has been pro-
posed in immunoradiotherapy protocols (Press et al., 1993),
it would be preferable to minimise this non-specific toxicity.
This could be done by using Po66 as the first part of a
two-step treatment. The principles of this technique were
outlined in the introduction. Po66 is a particularly good
candidate for such use. Its retention in tumours is prolonged,
even if the MAb fraction remaining in the circulation is
artificially reduced (Desrues et al., 1995).
Cancer treatment with radiolabelled MAbs raises impor-
tant problems of dosimetry. In the mathematical formulae
for the alculation ofthe radiation dose, it is usually assumed
that the irradiation source is uniformly distributed in the
tissue, which is obviously not the case for MAbs (Zalcberg et
al., 1981; Badger et al., 1986). Microscopic dosimetry seems
more appropriate for MAbs (Humm et al., 1990), but is
difficult to compute. Consequently, to appreciate the additive
effect of immunoradiotherapy and chemotherapy, animal
models such as that described here seem more suitable than
theoretical and in wvtro investigations. Treatment of lung
cancer in the mouse model described in the present work by
combining chemotherapy and tumoricidal doses of ['3'I]Po66
is curently under investigation in our laboratory.
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